Cumberland Pharmaceuticals Inc.
As of Oct 22, 2026, Cumberland Pharmaceuticals is in Stage 2, the uptrend phase, now in week 23 (since May 14, 2026). It closed at $8.48, 5.5% below its 52-week high and above its 200-day average, which is rising.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care
Is CPIX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CPIX among Drug Manufacturers - Specialty & Generic1st of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
Cumberland Pharmaceuticals: quick answers
What stage is Cumberland Pharmaceuticals in?
As of Oct 22, 2026, Cumberland Pharmaceuticals (CPIX) is in Stage 2, the uptrend phase. It entered Stage 2 on May 14, 2026 and is in week 23. What the four stages mean
Is Cumberland Pharmaceuticals in an uptrend?
Yes. Cumberland Pharmaceuticals is in a Stage 2 uptrend. It trades 78.3% above its 200-day average, which is rising.
How far is Cumberland Pharmaceuticals from its 52-week high?
Cumberland Pharmaceuticals closed at $8.48 on Oct 22, 2026, 5.5% below its 52-week high of $8.97. Its 52-week low is $1.47.
How has Cumberland Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Cumberland Pharmaceuticals is up 200.4% over the past year and up 174.8% so far in 2026.
Which sector and industry is Cumberland Pharmaceuticals in?
Cumberland Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.